More than 85% of GCC's estimated 1,200-1,500 HAE patients remain undiagnosed despite lanadelumab's 87% attack-rate reduction.

C1-inhibitor (Berinert) is the dominant acute agent across GCC emergency and ICU settings, SFDA-registered and available in major government hospitals. Icatibant (Firazyr) is second-line for acute attacks, with home self-administration limited by physician reluctance; most dosing remains hospital-administered rather than patient self-injected. Lanadelumab (Takhzyro), which delivered an 87% attack-rate reduction in the HELP trial, has been SFDA-registered in Saudi Arabia since 2022, but it sits outside the NPHC/MOH formulary for routine prophylaxis; access today runs through specialist prescription only, and an estimated 95% of GCC HAE patients are managed with acute on-demand therapy alone.

The scale of the underdiagnosis is the defining feature of the GCC HAE market: an estimated 1,200 to 1,500 patients exist across the region, yet the KFSH&RC HAE Registry counts fewer than 200 confirmed cases regionwide. Mean diagnostic delay runs 12 to 15 years in the GCC versus 8 to 10 years globally, driven by limited C4/C1-inhibitor testing outside tertiary centres, and annual ER visits per patient run 6 to 8 in the GCC versus 2 to 3 in the US/EU. Consanguinity elevates affected-kindred size: KFSH&RC series document 3 to 4 affected members per family versus 1.8 in European series.

Underdiagnosis, not drug access, is what keeps HAE prophylaxis rare in the GCC.

Five questions this report answers:

Q1 - What would trigger NPHC/MOH formulary coverage for lanadelumab prophylaxis in the GCC?

Q2 - How large is the true GCC HAE patient pool once diagnostic delay is accounted for?

Q3 - What is the ER-utilisation burden of acute-only HAE management compared with early prophylaxis?

Q4 - Why hasn't prophylaxis become standard of care despite lanadelumab's SFDA registration?

Q5 - How does consanguinity-driven family clustering create a distinct HAE screening opportunity?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#HereditaryAngioedema #HAE #GCC #Lanadelumab #RareDisease #MarketAccess

Live report page:  https://axlrx.ai/hereditary-angioedema/gcc/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-   hello@axlrx.ai

Web-   https://axlrx.ai/